103
Participants
Start Date
September 1, 2022
Primary Completion Date
May 17, 2024
Study Completion Date
May 17, 2024
Ruxolitinib Cream
Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.
Sadick Dermatology Sadick Research Group, New York
Empire Dermatology, East Syracuse
Iact Health, Columbus
Solutions Through Advanced Research, Inc, Jacksonville
Encore Medical Research, Llc Hollywood, Hollywood
Skin Research of South Florida, Llc, Miami
Well Pharma Medical Research Corp., Miami
Forward Clinical Trials, Tampa
International Clinical Research Tennessee Llc, Murfreesboro
Aventiv Research Inc-Dublin, Dublin
Apex Clinical Research Center, Mayfield Heights
Ohio Pediatric Research Association, Dayton
Northshore University Health System, Skokie
Skin Specialists Pc the Advanced Skin Research Center, Omaha
Meridian Clinical Research, Baton Rouge
Arkansas Research Trials, North Little Rock
Lynn Health Science Institute, Oklahoma City
Arlington Research Center, Arlington
Progressive Clinical Research, San Antonio
Dermatology Research Associates, Los Angeles
Peninsula Research Associates Pra, Rolling Hills Estates
First Oc Dermatology, Fountain Valley
Advanced Rx Clinical Research Group, Inc, Westminster
Acevedo Clinical Research, Miami
Sneeze Wheeze and Itch Associates Llc, Normal
Jordan Valley Medical Center, West Jordan
Dermatology Research Institute, Calgary
Dr. Chih-Ho Hong Medical Inc., Surrey
Lmc Manna Research (London), London
Manna Research Toronto, Toronto
K. Papp Clinical Research, Waterloo
Xlr8 Medical Research, Windsor
Centrum Medyczne Pratia Czestochowa, Częstochowa
Centrum Medyczne Angelius Provita, Katowice
Samodzielny Publiczny Szpital Kliniczny Nr 1, Lublin
Dermedic Dr. Zdybski, Ostrowiec Świętokrzyski
Centrum Medyczne Evimed, Warsaw
Klinika Ambroziak, Warsaw
Lead Sponsor
Incyte Corporation
INDUSTRY